Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Level Biotechnology 9-Day RSI Related Terms
ROCO:3118 vs VRTX, REGN, RVMD: 9-Day RSI Comparison
For the Biotechnology subindustry, Level Biotechnology's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a 9-Day RSI of 44.59 as of Aug. 05, 2026. According to the industry distribution chart, Level Biotechnology ranks #600 out of 1420 companies in the Biotechnology industry, placing it in the top 42.3%.
Is Level Biotechnology's 9-Day RSI too high?
Level Biotechnology's current 9-Day RSI is 44.59. The Biotechnology industry median 9-Day RSI is 49.37. Level Biotechnology's value of 44.59 is 9.7% below this industry median. Based on the distribution chart, Level Biotechnology ranks #600 out of 1420 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Level Biotechnology has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #600 out of 1420 companies for 9-Day RSI. This puts Level Biotechnology in the upper half of its industry. The industry median 9-Day RSI is 49.37. Level Biotechnology's value of 44.59 is 9.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 49.37, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Biotechnology's current 9-Day RSI of 44.59 is 9.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 49.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Biotechnology's current 9-Day RSI is 44.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.82, compared to a current price of NT$31.70 — trading 6.3% below its estimated fair value. The current 9-Day RSI is 44.59 and 9.7% below the Biotechnology industry median of 49.37. Level Biotechnology's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current 9-Day RSI is 44.59 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.70 is trading 6.3% below its estimated GF Value™ of NT$33.82.
GuruFocus considers Level Biotechnology to be Fairly Valued.
Key valuation signals for ROCO:3118:
9-Day RSI: 44.59
GF Value™: NT$33.82 vs. price of NT$31.70 (6.3% below fair value)
Industry Position: 9.7% below the Biotechnology median (#600 of 1420)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
75GF Score
Get the complete analysis for ROCO:3118
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
